Quarterly ResultAug 13, 2026, 04:13 PM
Aktis Oncology Completes IPO, Boosts Cash to $517.3M
AI Summary
Aktis Oncology, Inc. completed its Initial Public Offering in January 2026, raising approximately $334.4 million in net proceeds. This significantly strengthened the company's financial position, converting a stockholders' deficit into substantial equity. For the six months ended June 30, 2026, the company reported a net loss of $42.5 million on collaboration revenue of $6.6 million, but its liquidity remains strong with $517.3 million in cash and marketable securities.
Key Highlights
- Completed Initial Public Offering in January 2026, raising $334.4 million net.
- Preferred stock converted to 32.2 million common shares and 1.9 million Class A shares.
- Net loss for six months ended June 30, 2026, was $42.5 million.
- Collaboration revenue for the six months increased 117% to $6.6 million.
- Cash and marketable securities totaled $517.3 million as of June 30, 2026.
- Stockholders' equity improved to $484.8 million from a $146.1 million deficit.
- Liquidity sufficient to fund operations for at least 12 months.
Price Impact
More from AKTS